Abstract
The authors examine the clinical and pathologic characteristics of 73 patients undergoing primary retroperitoneal lymph node dissection (RPLND) with pathologic stage II disease who did not receive adjuvant chemotherapy. Of these patients who had normal serum tumor markers after RPLND, 19 of 73 (26%) had relapse of disease. Although they found that more positive nodes, larger metastases, and presence of extranodal extension increased the likelihood of recurrence, none of these factors was statistically significant.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
